# A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions

> **NCT01879683** · PHASE1 · COMPLETED · sponsor: **Allergan** · enrollment: 10 (actual)

## Conditions studied

- Chronic Interstitial Cystitis

## Interventions

- **DRUG:** LiRIS® 400 mg

## Key facts

- **NCT ID:** NCT01879683
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-05
- **Final completion:** 2014-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01879683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01879683, "A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01879683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*